Sara Mobarak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sara Mobarak has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Esmat Radmanesh
Department of Physiology, School of Medicine, Abadan University of Medical Sciences, Abadan, Iran
5 shared publications Esmat Radmanesh
Department of Medical Physiology, School of Medicine, Abadan University of Medical Sciences, Abadan, Iran
3 shared publicationsMorteza Mobarak
Clinical Research Development Unit, Taleghani Educational Hospital, Abadan University of Medical Sciences, Abadan, Iran
3 shared publicationsAlireza Hazbenejad
Student Research Committee, Abadan University of Medical Sciences, Abadan, Iran
2 shared publicationsFatemeh Maghsoudi
Department of Public Health, School of Health, Abadan University of Medical Sciences, Abadan, Iran
2 shared publicationsGholamali Eslami
Abadan University of medical Sciences, Abadan, Iran
2 shared publications
Latest Publications
- Open Access
- 16 January 2025
- Published by Wiley in Interdisciplinary Perspectives on Infectious Diseases
- Vol. 2025 (1) , 3134775
Evaluation of Emerging Antimicrobials Resistance in Nosocomial Infections Caused by E. coli : The Comparison Results of Observed Cases and Compartmental Model
Background: In recent years, the global rise of antibiotic‐resistant Escherichia coli ( E. coli ) has become a significant threat to public health. This study aimed to identify and track outbreaks of antibiotic resistance, specifically among the antibiotics used to treat nosocomial E. coli infections. Materials and Methods: This hospital‐based study utilized data from a nosocomial infection surveillance system to investigate reported cases of antibiotic resistance. The study analyzed the results of 12,954 antibiogram tests conducted across 57 hospitals in 31 provinces of Iran. The data was divided into two periods: the first and second halves of 2017. Before developing a predictive model for resistant E. coli cases, the model’s validity was tested using the first half of the year’s data. The predicted cases were then compared to the actual observed cases in 2017, with a statistically significant difference indicating an outbreak. Findings: The study found that, in 2017, hospitals in Iran experienced an outbreak of E. coli resistant to ampicillin and ceftazidime. This resistance was more prevalent than expected, highlighting the emergence of these drugs as major contributors to nosocomial E. coli infections. Conclusion: This study demonstrated the utility of the compartmental model in forecasting outbreaks of antibiotic‐resistant E. coli . It provides a framework for investigating similar outbreaks in the future, using diverse data sources and methodologies.
- 16 January 2025
- Published by Wiley in Interdisciplinary Perspectives on Infectious Diseases
- Vol. 2025 (1) , 3134775
Open AccessEvaluation of Emerging Antimicrobials Resistance in Nosocomial Infections Caused by E. coli : The Comparison Results of Observed Cases and Compartmental Model
Background: In recent years, the global rise of antibiotic‐resistant Escherichia coli ( E. coli ) has become a significant threat to public health. This study aimed to identify and track outbreaks of antibiotic resistance, specifically among the antibiotics used to treat nosocomial E. coli infections. Materials and Methods: This hospital‐based study utilized data from a nosocomial infection surveillance system to investigate reported cases of antibiotic resistance. The study analyzed the results of 12,954 antibiogram tests conducted across 57 hospitals in 31 provinces of Iran. The data was divided into two periods: the first and second halves of 2017. Before developing a predictive model for resistant E. coli cases, the model’s validity was tested using the first half of the year’s data. The predicted cases were then compared to the actual observed cases in 2017, with a statistically significant difference indicating an outbreak. Findings: The study found that, in 2017, hospitals in Iran experienced an outbreak of E. coli resistant to ampicillin and ceftazidime. This resistance was more prevalent than expected, highlighting the emergence of these drugs as major contributors to nosocomial E. coli infections. Conclusion: This study demonstrated the utility of the compartmental model in forecasting outbreaks of antibiotic‐resistant E. coli . It provides a framework for investigating similar outbreaks in the future, using diverse data sources and methodologies.
- Open Access
- 22 July 2023
- Published by Maad Rayan Publishing Company in Disease and Diagnosis
- Vol. 13 (1) , 18-25
The Effect of a Low Dose of Vitamin C in Patients With COVID-19: A Double-Blind Randomized Controlled Trial
Background: Vitamin C is a micronutrient with anti-inflammatory and free radical scavenging properties that can strengthen the body’s immune system. In this study, it was attempted to assess the clinical efficiency of oral vitamin C in treating COVID-19. Materials and Methods: This double-blind randomized clinical trial was conducted on 401 patients hospitalized in Taleghani hospital, Abadan, over 18 years of age and with confirmed COVID-19 infection, from November 2020 to May 2021. The patients were randomly assigned to intervention groups (201 people, two tablets per day, each containing 500 mg of vitamin C) and the control group (200 people, placebo, containing starch received for five days). Improvements in clinical symptoms, death from baseline to the 28-day follow-up after the intervention, hospital length of stay, and laboratory values of C-reactive protein (CRP) were some of the considered outcome variables. Results: No significant difference was observed between the two groups in terms of the daily improvement of clinical symptoms and the odds of healing from each symptom increased by about 48-50%. The difference in the length of hospital stay between the two groups was close to significant (P=0.051). There was no significant difference in mortality between the two groups (P=0.8). There was no difference between the two groups in the laboratory parameters, except for alkaline phosphatase (P=0.03). Conclusion: Vitamin C had no significant effect on improving patients’ clinical symptoms such as fatigue, fever, cough, and shortness of breath.
- 22 July 2023
- Published by Maad Rayan Publishing Company in Disease and Diagnosis
- Vol. 13 (1) , 18-25
Open AccessThe Effect of a Low Dose of Vitamin C in Patients With COVID-19: A Double-Blind Randomized Controlled Trial
Background: Vitamin C is a micronutrient with anti-inflammatory and free radical scavenging properties that can strengthen the body’s immune system. In this study, it was attempted to assess the clinical efficiency of oral vitamin C in treating COVID-19. Materials and Methods: This double-blind randomized clinical trial was conducted on 401 patients hospitalized in Taleghani hospital, Abadan, over 18 years of age and with confirmed COVID-19 infection, from November 2020 to May 2021. The patients were randomly assigned to intervention groups (201 people, two tablets per day, each containing 500 mg of vitamin C) and the control group (200 people, placebo, containing starch received for five days). Improvements in clinical symptoms, death from baseline to the 28-day follow-up after the intervention, hospital length of stay, and laboratory values of C-reactive protein (CRP) were some of the considered outcome variables. Results: No significant difference was observed between the two groups in terms of the daily improvement of clinical symptoms and the odds of healing from each symptom increased by about 48-50%. The difference in the length of hospital stay between the two groups was close to significant (P=0.051). There was no significant difference in mortality between the two groups (P=0.8). There was no difference between the two groups in the laboratory parameters, except for alkaline phosphatase (P=0.03). Conclusion: Vitamin C had no significant effect on improving patients’ clinical symptoms such as fatigue, fever, cough, and shortness of breath.
- Open Access
- 29 June 2023
- Published by Maad Rayan Publishing Company in Avicenna Journal of Clinical Microbiology and Infection
- Vol. 10 (2) , 70-74
Investigation of the Most Common Bacterial Strains in Diabetic Foot Ulcer Patients
Background: Diabetes has been one of the most prevalent medical illnesses, and diabetic foot ulcer (DFU) infections are the main causes of hospitalization in diabetics. The present study aimed to investigate the factors contributing to DFUs in patients referred to Taleghani Hospital in Abadan. Methods: In this study, the data of 316 diabetic patients with DFUs referred to Taleghani Hospital in Abadan from March 21, 2019, to March 19, 2020, were analyzed by SPSS version 22.0. Results: The study revealed that out of the 316 patients, 212 (67.1%) were male and 104 (32.9%) were female. Additionally, 64.3% of them had type 2 diabetes. Most of the patients had third-degree ulcers (60.4%) and 26.9% had amputations. Staphylococcus aureus (34.5%) and Pseudomonas aeruginosa (30.4%) were the most prevalent bacteria isolated from DFUs. The highest frequency of antibiotic resistance was reported for Cotrimoxazole (33%) and Tetracycline (28.2%). Conclusion: In conclusion, Gram-positive bacteria had a higher prevalence compared to gram-negative bacteria. It is essential to conduct periodic examinations to reduce the risk of health-threatening complications in diabetic patients.
- 29 June 2023
- Published by Maad Rayan Publishing Company in Avicenna Journal of Clinical Microbiology and Infection
- Vol. 10 (2) , 70-74
Open AccessInvestigation of the Most Common Bacterial Strains in Diabetic Foot Ulcer Patients
Background: Diabetes has been one of the most prevalent medical illnesses, and diabetic foot ulcer (DFU) infections are the main causes of hospitalization in diabetics. The present study aimed to investigate the factors contributing to DFUs in patients referred to Taleghani Hospital in Abadan. Methods: In this study, the data of 316 diabetic patients with DFUs referred to Taleghani Hospital in Abadan from March 21, 2019, to March 19, 2020, were analyzed by SPSS version 22.0. Results: The study revealed that out of the 316 patients, 212 (67.1%) were male and 104 (32.9%) were female. Additionally, 64.3% of them had type 2 diabetes. Most of the patients had third-degree ulcers (60.4%) and 26.9% had amputations. Staphylococcus aureus (34.5%) and Pseudomonas aeruginosa (30.4%) were the most prevalent bacteria isolated from DFUs. The highest frequency of antibiotic resistance was reported for Cotrimoxazole (33%) and Tetracycline (28.2%). Conclusion: In conclusion, Gram-positive bacteria had a higher prevalence compared to gram-negative bacteria. It is essential to conduct periodic examinations to reduce the risk of health-threatening complications in diabetic patients.
- Open Access
- 10 June 2023
- Published by Brieflands in International Journal of Infection
- Vol. 9 (4)
Laboratory Diagnostic Tests in Patients with Sepsis
Background: Sepsis is a syndrome involving physiological, pathological, and biochemical abnormalities caused by infection and leads to the dysfunction of various organs, including the liver and kidneys. It can lead to high mortality rates. Objectives: This study aimed to evaluate the hepatic, renal, and coagulation diagnostic markers in patients with sepsis. Methods: This cross-sectional analytical study was performed on patients with sepsis admitted to Abadan and Khorramshahr educational hospitals during March 21 2019-March 19, 2020. The hospital information system (HIS) collected the information of 305 patients with sepsis, including hepatic, coagulation, and renal diagnostic factors, as well as age and gender. Results: It was observed that the mean of blood sugar (BS) (145.82 ± 105.10 mg/dL), BUN (29.64 ± 27.41 mg/dL), and creatinine (1.69 ± 1.9 mg/dL) in sepsis patients was higher than normal. In addition, the mean of diagnostic markers of the liver, including ALT (47.27 ± 76.63 U/L), AST (74.38 ± 163.96 U/L), LDH (684.69 ± 383.96 U/L), total bilirubin (1.39 ± 1.02 mg/dL), and direct bilirubin (0.60 ± 0.65 mg/dL), was higher than normal. The mean of PT (16.73 ± 9.31 sec) and INR (1.72 ± 1.53) was also higher than the normal level. Conclusions: In hospitalized patients with sepsis, BS, renal diagnostic markers, hepatic diagnostic markers, and coagulation markers are higher than normal, indicating the destructive effect of sepsis on kidney and liver function.
- 10 June 2023
- Published by Brieflands in International Journal of Infection
- Vol. 9 (4)
Open AccessLaboratory Diagnostic Tests in Patients with Sepsis
Background: Sepsis is a syndrome involving physiological, pathological, and biochemical abnormalities caused by infection and leads to the dysfunction of various organs, including the liver and kidneys. It can lead to high mortality rates. Objectives: This study aimed to evaluate the hepatic, renal, and coagulation diagnostic markers in patients with sepsis. Methods: This cross-sectional analytical study was performed on patients with sepsis admitted to Abadan and Khorramshahr educational hospitals during March 21 2019-March 19, 2020. The hospital information system (HIS) collected the information of 305 patients with sepsis, including hepatic, coagulation, and renal diagnostic factors, as well as age and gender. Results: It was observed that the mean of blood sugar (BS) (145.82 ± 105.10 mg/dL), BUN (29.64 ± 27.41 mg/dL), and creatinine (1.69 ± 1.9 mg/dL) in sepsis patients was higher than normal. In addition, the mean of diagnostic markers of the liver, including ALT (47.27 ± 76.63 U/L), AST (74.38 ± 163.96 U/L), LDH (684.69 ± 383.96 U/L), total bilirubin (1.39 ± 1.02 mg/dL), and direct bilirubin (0.60 ± 0.65 mg/dL), was higher than normal. The mean of PT (16.73 ± 9.31 sec) and INR (1.72 ± 1.53) was also higher than the normal level. Conclusions: In hospitalized patients with sepsis, BS, renal diagnostic markers, hepatic diagnostic markers, and coagulation markers are higher than normal, indicating the destructive effect of sepsis on kidney and liver function.
- Open Access
- 3 May 2023
- Published by Maad Rayan Publishing Company in Disease and Diagnosis
- Vol. 12 (3) , 118-123
Evaluation of laboratory diagnostic markers in diabetic patients with COVID-19
Background: Diabetes mellitus is the most common chronic metabolic disorder that increases both susceptibility and mortality rates in patients with the coronavirus disease 2019 (COVID-19). We conducted a study on diabetic patients with COVID-19 to investigate the relationship between laboratory indicators and peripheral oxygen saturation (SPO2 ). Methods: In this analytical-cross-sectional study, the required information of diabetic patients with COVID-19 admitted to Taleghani educational hospital in Abadan from March 20, 2020 to March 19, 2021 was obtained by referring to the hospital information system of Abadan University of Medical Sciences and patient files. Results: Two hundred patients were studied, of which 88 (44%) were men and 112 (56%) were women. The mean age of the studied patients was 60.57±14.84. Among all the investigated markers, blood urea nitrogen (BUN), serum glutamate oxalate transaminase (SGOT), serum glutamic-pyruvic transaminase (SGPT), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), lactate dehydrogenase (LDH), and respiratory rate (RR) were higher than the normal range, while SPO2 was lower than the normal range. Based on the linear regression analysis results, a significant relationship was observed between the decrease in SPO2 of patients with disease outcome, duration of hospitalization in the intensive care unit (P<0.001), RR (P<0.001), mean corpuscular volume (MCV) (P=0.02), CRP+3 (P=0.002), platelet (PTT) (P=0.03), alkaline phosphatase (ALP) (P=0.002), and LDH (P=0.003). Conclusion: The results showed that some laboratory diagnostic markers were higher than the normal range, while SPO2 was lower than the normal range. Moreover, a significant relationship was found between SPO2 index and disease outcome, duration of hospitalization in intensive care unit (ICU), and some diagnostic markers of the liver, inflammation, and coagulation.
- 3 May 2023
- Published by Maad Rayan Publishing Company in Disease and Diagnosis
- Vol. 12 (3) , 118-123
Open AccessEvaluation of laboratory diagnostic markers in diabetic patients with COVID-19
Background: Diabetes mellitus is the most common chronic metabolic disorder that increases both susceptibility and mortality rates in patients with the coronavirus disease 2019 (COVID-19). We conducted a study on diabetic patients with COVID-19 to investigate the relationship between laboratory indicators and peripheral oxygen saturation (SPO2 ). Methods: In this analytical-cross-sectional study, the required information of diabetic patients with COVID-19 admitted to Taleghani educational hospital in Abadan from March 20, 2020 to March 19, 2021 was obtained by referring to the hospital information system of Abadan University of Medical Sciences and patient files. Results: Two hundred patients were studied, of which 88 (44%) were men and 112 (56%) were women. The mean age of the studied patients was 60.57±14.84. Among all the investigated markers, blood urea nitrogen (BUN), serum glutamate oxalate transaminase (SGOT), serum glutamic-pyruvic transaminase (SGPT), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), lactate dehydrogenase (LDH), and respiratory rate (RR) were higher than the normal range, while SPO2 was lower than the normal range. Based on the linear regression analysis results, a significant relationship was observed between the decrease in SPO2 of patients with disease outcome, duration of hospitalization in the intensive care unit (P<0.001), RR (P<0.001), mean corpuscular volume (MCV) (P=0.02), CRP+3 (P=0.002), platelet (PTT) (P=0.03), alkaline phosphatase (ALP) (P=0.002), and LDH (P=0.003). Conclusion: The results showed that some laboratory diagnostic markers were higher than the normal range, while SPO2 was lower than the normal range. Moreover, a significant relationship was found between SPO2 index and disease outcome, duration of hospitalization in intensive care unit (ICU), and some diagnostic markers of the liver, inflammation, and coagulation.
- Open Access
- 1 April 2023
- Published by Maad Rayan Publishing Company in Disease and Diagnosis
- Vol. 12 (2) , 70-76
The Relationship Between SpO2 and Laboratory Diagnostic Markers of Cardiovascular Patients with COVID-19
Background: In December 2019, a new virus, the coronavirus disease 2019 (COVID-19) was identified as the cause of a cluster of cases of pneumonia of unknown etiology in Wuhan, China. The COVID-19 disease increases cardiovascular events both directly and indirectly. This study aimed to investigate the laboratory diagnostic markers of cardiovascular patients with COVID-19 in Ayatollah Taleghani hospital in Abadan from March 20, 2019 to March 19, 2020. Materials and Methods: This study is a cross-sectional analytical study. Some demographic, laboratory, and clinical information of 200 cardiovascular patients with COVID-19 admitted to Taleghani hospital, Abadan, was received randomly by referring to the medical records section and medical records section and health information system (HIS) as well as searching in the patient records. Inclusion criteria included cardiovascular patients with COVID-19 who had been admitted to Ayatollah Taleghani hospital in Abadan with the diagnosis of a cardiologist and infectious disease specialist, and those whose information was available in HIS. The results were analyzed using SPSS software version 24. Results: The mean age of cardiovascular patients with COVID-19 was reported to be 66.98±18.14. The results revealed that the mean of fasting blood sugar (FBS), serum glutamic oxaloacetic transaminase (SGOT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), creatinine (Cr), blood urea nitrogen (BUN), and erythrocyte sedimentation rate (ESR) was higher than the normal level in these patients. In addition, the mean oxygen saturation (SpO2) was observed to be lower than normal. Reducing the level of SpO2 to less than 90% was significantly related to increasing age, death, patients with a history of lung disease, the duration of hospitalization in ICU, and intubation. This reduction also led to an increase in respiratory rate (RR), LDH, ESR, and C-reactive protein (CRP+1) in cardiovascular patients with COVID-19. Conclusion: In cardiovascular patients with COVID-19, FBS, some kidney markers, liver markers, and inflammatory markers were observed to be higher than normal, and a significant relationship was observed between the reduction of SpO2 and some laboratory diagnostic markers, which requires extensive studies with larger sample size.
- 1 April 2023
- Published by Maad Rayan Publishing Company in Disease and Diagnosis
- Vol. 12 (2) , 70-76
Open AccessThe Relationship Between SpO2 and Laboratory Diagnostic Markers of Cardiovascular Patients with COVID-19
Background: In December 2019, a new virus, the coronavirus disease 2019 (COVID-19) was identified as the cause of a cluster of cases of pneumonia of unknown etiology in Wuhan, China. The COVID-19 disease increases cardiovascular events both directly and indirectly. This study aimed to investigate the laboratory diagnostic markers of cardiovascular patients with COVID-19 in Ayatollah Taleghani hospital in Abadan from March 20, 2019 to March 19, 2020. Materials and Methods: This study is a cross-sectional analytical study. Some demographic, laboratory, and clinical information of 200 cardiovascular patients with COVID-19 admitted to Taleghani hospital, Abadan, was received randomly by referring to the medical records section and medical records section and health information system (HIS) as well as searching in the patient records. Inclusion criteria included cardiovascular patients with COVID-19 who had been admitted to Ayatollah Taleghani hospital in Abadan with the diagnosis of a cardiologist and infectious disease specialist, and those whose information was available in HIS. The results were analyzed using SPSS software version 24. Results: The mean age of cardiovascular patients with COVID-19 was reported to be 66.98±18.14. The results revealed that the mean of fasting blood sugar (FBS), serum glutamic oxaloacetic transaminase (SGOT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), creatinine (Cr), blood urea nitrogen (BUN), and erythrocyte sedimentation rate (ESR) was higher than the normal level in these patients. In addition, the mean oxygen saturation (SpO2) was observed to be lower than normal. Reducing the level of SpO2 to less than 90% was significantly related to increasing age, death, patients with a history of lung disease, the duration of hospitalization in ICU, and intubation. This reduction also led to an increase in respiratory rate (RR), LDH, ESR, and C-reactive protein (CRP+1) in cardiovascular patients with COVID-19. Conclusion: In cardiovascular patients with COVID-19, FBS, some kidney markers, liver markers, and inflammatory markers were observed to be higher than normal, and a significant relationship was observed between the reduction of SpO2 and some laboratory diagnostic markers, which requires extensive studies with larger sample size.
- Open Access
- 28 November 2021
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 77 (3) , 758-766
Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)
Background: The combination of sofosbuvir and daclatasvir has shown preliminary efficacy for hospitalized patients with COVID-19 in four open-label studies with small sample sizes. This larger trial aimed to assess if the addition of sofosbuvir/daclatasvir to standard care improved clinical outcomes in hospitalized patients with COVID-19. Methods: This was a placebo-controlled, double-blind, randomized clinical trial in adults hospitalized with COVID-19 at 19 hospitals in Iran. Patients were randomized to oral sofosbuvir/daclatasvir 400/60 mg once-daily or placebo in addition to standard of care. Patients were included if they had positive PCR or diagnostic chest CT, O2 saturation <95% and compatible symptoms. The primary outcome was hospital discharge within 10 days of randomization. Secondary outcomes included mortality and time to clinical events. The trial is registered on the Iran Registry of Clinical Trials under IRCT20200624047908N1. Results: Between July and October 2020, 1083 patients were randomized to either the sofosbuvir/daclatasvir arm (n = 541) or the placebo arm (n = 542). No significant difference was observed in the primary outcome of hospital discharge within 10 days, which was achieved by 415/541 (77%) in the sofosbuvir/daclatasvir arm and 411/542 (76%) in the placebo arm [risk ratio (RR) 1.01, 95% CI 0.95–1.08, P = 0.734]. In-hospital mortality was 60/541 (11%) in the sofosbuvir/daclatasvir arm versus 55/542 (10%) in the placebo arm (RR 1.09, 95% CI 0.77–1.54, P = 0.615). No differences were observed in time to hospital discharge or time to in-hospital mortality. Conclusions: We observed no significant effect of sofosbuvir/daclatasvir versus placebo on hospital discharge or survival in hospitalized COVID-19 patients.
- 28 November 2021
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 77 (3) , 758-766
Open AccessEvaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)
Background: The combination of sofosbuvir and daclatasvir has shown preliminary efficacy for hospitalized patients with COVID-19 in four open-label studies with small sample sizes. This larger trial aimed to assess if the addition of sofosbuvir/daclatasvir to standard care improved clinical outcomes in hospitalized patients with COVID-19. Methods: This was a placebo-controlled, double-blind, randomized clinical trial in adults hospitalized with COVID-19 at 19 hospitals in Iran. Patients were randomized to oral sofosbuvir/daclatasvir 400/60 mg once-daily or placebo in addition to standard of care. Patients were included if they had positive PCR or diagnostic chest CT, O2 saturation <95% and compatible symptoms. The primary outcome was hospital discharge within 10 days of randomization. Secondary outcomes included mortality and time to clinical events. The trial is registered on the Iran Registry of Clinical Trials under IRCT20200624047908N1. Results: Between July and October 2020, 1083 patients were randomized to either the sofosbuvir/daclatasvir arm (n = 541) or the placebo arm (n = 542). No significant difference was observed in the primary outcome of hospital discharge within 10 days, which was achieved by 415/541 (77%) in the sofosbuvir/daclatasvir arm and 411/542 (76%) in the placebo arm [risk ratio (RR) 1.01, 95% CI 0.95–1.08, P = 0.734]. In-hospital mortality was 60/541 (11%) in the sofosbuvir/daclatasvir arm versus 55/542 (10%) in the placebo arm (RR 1.09, 95% CI 0.77–1.54, P = 0.615). No differences were observed in time to hospital discharge or time to in-hospital mortality. Conclusions: We observed no significant effect of sofosbuvir/daclatasvir versus placebo on hospital discharge or survival in hospitalized COVID-19 patients.
- Open Access
- 27 November 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (4) , 1457-1464
Profiling serum levels of glutathione reductase and interleukin‐10 in positive and negative‐PCR COVID‐19 outpatients: A comparative study from southwestern Iran
Since the outbreak of COVID‐19 in China, it has rapidly spread across many other countries. We evaluated antioxidant defense systems and inflammatory status related to the SARS‐CoV2 infection in a population from southwestern Iran. Comorbidities and clinical symptoms of 104 subjects (comprising negative and positive‐PCR COVID‐19 outpatients) were assessed. Serum concentrations of glutathione reductase (GR) and interleukin‐10 (IL‐10) were measured using ELISA. In the positive‐PCR group, follow‐ups on clinical symptoms were carried out for 28 days at 7‐day intervals. In the positive‐PCR group, hypertension, diabetes, liver disease, chronic heart disease, and chronic kidney disease were the most common comorbidities. In the general category of symptoms, we found a significant difference between negative and positive‐PCR groups, except regarding runny noses. In the pulmonary category, there was a significant difference between the two groups except in terms of chest pain. We also determined a significant difference in neurologic symptoms, except for ear pain, between negative and positive‐PCR groups. We also found significantly lower levels of GR but higher levels of IL‐10 in the positive‐PCR group ( p = 0.000 for both). In the positive‐PCR group, serum levels of IL‐10 (odds ratio = 0.914, p = 0.012) decreased the chances of neurological symptoms occurring over time. The antioxidant defense systems of positive‐PCR outpatients failed as demonstrated by a reduction in the serum levels of GR. We also indicated a dysregulation in the immune response against COVID‐19, characterized by changes in serum IL‐10 levels.
- 27 November 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (4) , 1457-1464
Open AccessProfiling serum levels of glutathione reductase and interleukin‐10 in positive and negative‐PCR COVID‐19 outpatients: A comparative study from southwestern Iran
Since the outbreak of COVID‐19 in China, it has rapidly spread across many other countries. We evaluated antioxidant defense systems and inflammatory status related to the SARS‐CoV2 infection in a population from southwestern Iran. Comorbidities and clinical symptoms of 104 subjects (comprising negative and positive‐PCR COVID‐19 outpatients) were assessed. Serum concentrations of glutathione reductase (GR) and interleukin‐10 (IL‐10) were measured using ELISA. In the positive‐PCR group, follow‐ups on clinical symptoms were carried out for 28 days at 7‐day intervals. In the positive‐PCR group, hypertension, diabetes, liver disease, chronic heart disease, and chronic kidney disease were the most common comorbidities. In the general category of symptoms, we found a significant difference between negative and positive‐PCR groups, except regarding runny noses. In the pulmonary category, there was a significant difference between the two groups except in terms of chest pain. We also determined a significant difference in neurologic symptoms, except for ear pain, between negative and positive‐PCR groups. We also found significantly lower levels of GR but higher levels of IL‐10 in the positive‐PCR group ( p = 0.000 for both). In the positive‐PCR group, serum levels of IL‐10 (odds ratio = 0.914, p = 0.012) decreased the chances of neurological symptoms occurring over time. The antioxidant defense systems of positive‐PCR outpatients failed as demonstrated by a reduction in the serum levels of GR. We also indicated a dysregulation in the immune response against COVID‐19, characterized by changes in serum IL‐10 levels.
- Open Access
The Association between Vitamin D and Zinc Status and the Progression of Clinical Symptoms among Outpatients Infected with SARS-CoV-2 and Potentially Non-Infected Participants: A Cross-Sectional Study
Vitamin D and zinc are important components of nutritional immunity. This study compared the serum concentrations of 25-hydroxyvitamin D (25(OH)D) and zinc in COVID-19 outpatients with those of potentially non-infected participants. The association of clinical symptoms with vitamin D and zinc status was also examined. A checklist and laboratory examination were applied to collect data in a cross-sectional study conducted on 53 infected outpatients with COVID-19 and 53 potentially non-infected participants. Serum concentration of 25(OH)D were not significantly lower in patients with moderate illness (19 ± 12 ng/mL) than patients with asymptomatic or mild illness (29 ± 18 ng/mL), with a trend noted for a lower serum concentration of 25(OH)D in moderate than asymptomatic or mild illness patients (p = 0.054). Infected patients (101 ± 18 µg/dL) showed a lower serum concentration of zinc than potentially non-infected participants (114 ± 13 µg/dL) (p = 0.01). Patients with normal (odds ratio (OR), 0.19; p ≤ 0.001) and insufficient (OR, 0.3; p = 0.007) vitamin D status at the second to seventh days of disease had decreased OR of general symptoms compared to patients with vitamin D deficiency. This study revealed the importance of 25(OH)D measurement to predict the progression of general and pulmonary symptoms and showed that infected patients had significantly lower zinc concentrations than potentially non-infected participants.
Open AccessThe Association between Vitamin D and Zinc Status and the Progression of Clinical Symptoms among Outpatients Infected with SARS-CoV-2 and Potentially Non-Infected Participants: A Cross-Sectional Study
Vitamin D and zinc are important components of nutritional immunity. This study compared the serum concentrations of 25-hydroxyvitamin D (25(OH)D) and zinc in COVID-19 outpatients with those of potentially non-infected participants. The association of clinical symptoms with vitamin D and zinc status was also examined. A checklist and laboratory examination were applied to collect data in a cross-sectional study conducted on 53 infected outpatients with COVID-19 and 53 potentially non-infected participants. Serum concentration of 25(OH)D were not significantly lower in patients with moderate illness (19 ± 12 ng/mL) than patients with asymptomatic or mild illness (29 ± 18 ng/mL), with a trend noted for a lower serum concentration of 25(OH)D in moderate than asymptomatic or mild illness patients (p = 0.054). Infected patients (101 ± 18 µg/dL) showed a lower serum concentration of zinc than potentially non-infected participants (114 ± 13 µg/dL) (p = 0.01). Patients with normal (odds ratio (OR), 0.19; p ≤ 0.001) and insufficient (OR, 0.3; p = 0.007) vitamin D status at the second to seventh days of disease had decreased OR of general symptoms compared to patients with vitamin D deficiency. This study revealed the importance of 25(OH)D measurement to predict the progression of general and pulmonary symptoms and showed that infected patients had significantly lower zinc concentrations than potentially non-infected participants.